Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts.

[1]  G. Santulli,et al.  SGLT2 Inhibitors in Cardiovascular Medicine. , 2021, European heart journal. Cardiovascular pharmacotherapy.

[2]  Guanwei Fan,et al.  SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism , 2021, Heart Failure Reviews.

[3]  G. Qin,et al.  Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2021, Frontiers in Endocrinology.

[4]  M. Jardine,et al.  SGLT2 inhibitors may offer benefit beyond diabetes , 2020, Nature Reviews Nephrology.

[5]  K. Node,et al.  How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition? , 2020, Cardiovascular Diabetology.

[6]  C. Napoli,et al.  Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development , 2020, Journal of the American Heart Association.

[7]  Abdul Waheed Khan,et al.  Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD , 2020, Circulation research.

[8]  Sandeep R. Das,et al.  2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2020, Journal of the American College of Cardiology.

[9]  X. Qu,et al.  Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes , 2020, Frontiers in Endocrinology.

[10]  C. Napoli,et al.  Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients. , 2020, Journal of the American College of Cardiology.

[11]  A. Akhmedov,et al.  Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy , 2019, European heart journal.

[12]  S. Verma,et al.  Empagliflozin Increases Cardiac Energy Production in Diabetes , 2018, JACC. Basic to translational science.

[13]  J. Sowers,et al.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity , 2018, Circulation research.

[14]  J. Shaw,et al.  Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. , 2018, Journal of the American College of Cardiology.

[15]  B. Gerber,et al.  Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging , 2017, European heart journal cardiovascular Imaging.

[16]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[17]  G. Paolisso,et al.  Ergothioneine oxidation in the protection against high-glucose induced endothelial senescence: Involvement of SIRT1 and SIRT6. , 2016, Free radical biology & medicine.

[18]  K. Tsuchiya,et al.  Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction , 2016, PloS one.

[19]  L. Badano,et al.  European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation. , 2015, European heart journal cardiovascular Imaging.

[20]  V. Fuster,et al.  The relationships between cardiovascular disease and diabetes: focus on pathogenesis. , 2014, Endocrinology and metabolism clinics of North America.

[21]  W. Garvey,et al.  Limitations in the Use of Indices Using Glucose and Insulin Levels to Predict Insulin Sensitivity , 2013, Diabetes Care.

[22]  C. Pollock,et al.  Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy? , 2013, PloS one.

[23]  G. Paolisso,et al.  Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation , 2012, Diabetologia.

[24]  S. Park,et al.  Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea. , 2005, Metabolism: clinical and experimental.

[25]  Jennifer Y. Liu,et al.  Glycemic Control and Heart Failure Among Adult Patients With Diabetes , 2001, Circulation.